2026-GenuineBiotech-真实生物⎢ Improve Human Health Through Genuine Innovation

*The search scope is limited to the products and news section of this site

中文

News Center

Company News

Genuine Biotech Recognized as "Drug, Device, and Cosmetic Enterprise with Outstanding Performance in Drug, Device, and Cosmetic Adverse Reaction Monitoring and Evaluation in 2025"

Recently, the National Center for ADR Monitoring issued the "Announcement on Commending the Entities with Outstanding Performance in National Drug, Device, and Cosmetic Adverse Reaction Monitoring and Evaluation in 2025", and Genuine Biotech was rated as a "Drug, Device, and Cosmetic Enterprise with Outstanding Performance in Drug, Device, and Cosmetic Adverse Reaction Monitoring and Evaluation in 2025".
2026-03-04
Clinical Trial of Genuine Biotech's Azvudine in Combination with PD-1 Monoclonal Antibody in the Treatment of Advanced Solid Tumors Approved by the National Medical Products Administration

On Feb. 13, 2026, Henan Genuine Biotech Co., Ltd. announced that the clinical trial of self-developed anti-tumor drug GEN-725 tablets (Azvudine) in combination with PD-1 monoclonal antibody in the treatment of advanced solid tumors was approved by the National Medical Products Administration.
2026-02-27
Genuine Biotech Announces Appointment of Mr. Gao Jun as Chief Financial Officer

On January 21, 2026, Genuine Biotech officially announced that Mr. Gao Jun joined Genuine Biotech as Chief Financial Officer (CFO) to take charge of the Company's finance, capital operation, and compliance system improvement.
2026-01-23